KeyBanc lowered the firm’s price target on Phreesia (PHR) to $28 from $30 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- Phreesia price target lowered to $34 from $36 at DA Davidson
- Phreesia participates in a conference call with Jefferies
- Phreesia’s Earnings Call: Strong Growth and Positive Outlook
- Phreesia’s Strong Market Position and Financial Performance Justify Buy Rating Amid Positive Outlook for FY 2026
- Phreesia’s Strong Financial Performance and Growth Potential Justifies Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue